GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
PR Newswire —
- Phase 2 IND submission targeted for the second half of 2026 - Demonstrating the competitiveness of GC Biopharma's mRNA platform YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, announced today that Ministry of Food...